The text starts here.

News Release

FOR IMMEDIATE RELEASE
June 18, 2004

Sanko Junyaku Co., Ltd., Subsidiary of Eisai Co., Ltd., to Launch
New DCP Diagnostic Test Kit for Hepatocellular Carcinoma (HCC),
LUMIPULSE(R) PIVKA-II EISAI

Sanko Junyaku Co., Ltd.
FUJIREBIO INC.
Eisai Co., Ltd.

Sanko Junyaku Co., Ltd., Subsidiary of Eisai Co., Ltd., to Launch
New DCP Diagnostic Test Kit for Hepatocellular Carcinoma (HCC),
LUMIPULSE(R) PIVKA-II EISAI


Sanko Junyaku Co., Ltd. (Headquarters: Tokyo, President: Masao Jimbo), FUJIREBIO INC. (Headquarters: Tokyo, President: Hiromasa Suzuki), and Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announced that Sanko Junyaku will launch on August 3, 2004, LUMIPULSE(R) PIVKA-II EISAI, a test kit (in vitro diagnostics) to determine Des-gamma-Carboxy-Prothrombin, equal to and known as PIVKA-II in Japan ("DCP") and a marker of HCC. The test kit will be used for LUMIPULSE(R), automatic chemiluminescent enzyme immunoassay system developed and marketed by FUJIREBIO.


This test kit was developed by Sanko Junyaku, FUJIREBIO, and Eisai under a joint research agreement, and was approved for manufacture and sales in Japan. Under a manufacturing and supply agreement and a cooperative sales agreement, this test kit will be manufactured by FUJIREBIO, distributed by Sanko Junyaku, and Eisai will cooperate with Sanko Junyaku in the promotion of this reagent.


The reagent for measuring PIVKA-II has been widely used in HCC diagnosis because of its high specificity to HCC. Currently, Sanko Junyaku manufactures and markets the test kit for PIVKA-II under the product names of EITEST(R) PIVKA-II and PICOLUMI(R) PIVKA-II. The new PIVKA-II test kit, specially designed for LUMIPULSE(R), is expected to have greater ease of use and contribute to the improved benefits of patients.


Sanko Junyaku forecasts sales of 700 million yen for LUMIPULSE(R) PIVKA-II EISAI in fiscal year 2006.



Contacts:
Sanko Junyaku Co., Ltd.  
Administrative Dept.
Kazunori Nishina

03-3865-4311
FUJIREBIO INC.
IR & Public Relations Team

03-5695-9268
Eisai Co., Ltd.
Corporate Communications Dept.

03-3817-5120



[ The product outline, explanation of terms, and brief profiles of the involved companies are attached below for reference. ]



<FOR REFERENCE>

[ Product Outline ]


Product name : LUMIPULSE(R) PIVKA-II EISAI
Indication for use : Detection of abnormal prothrombin (PIVKA-II) in serum
Direction for use : Testing reagent exclusively for LUMIPULSE(R)-f (forte)
Packaging : Kit for 84 tests
Recommended price : 142,800 yen
Manufacturer : FUJIREBIO INC.
Distributor : Sanko Junyaku Co., Ltd.
Co-distributor : Eisai Co., Ltd.

*The test kit used in combination with the above product (sold separately)
Product name : Standard Solution PIVKA-II Set
Direction for use : Testing reagent exclusively for LUMIPULSE(R)-f (forte)
Packaging : Kit containing the antigen at 5 different concentration levels 3
Recommended price : 22,000 yen
Manufacturer : FUJIREBIO INC.
Distributor : Sanko Junyaku Co., Ltd.
Co-distributor : Eisai Co., Ltd.


[ Explanation of Terms ]

1. Automatic Chemiluminescent Enzyme Immunoassay (CLEIA) System

An automated enzyme immunoassay method utilizing a chemiluminescent substrate.
Trace materials in the living body are detected and measured using chemiluminescent enzyme reaction.

2. Hepatocellular Carcinoma (HCC)

HCC makes up most of the diagnosed liver cancer cases, and is the fourth leading cause of death in all types of malignant tumors in Japan.
Since many cases of HCC are developed from chronic viral hepatitis and/or hepatic cirrhosis, frequent and detailed monitoring of the pathologic process is key to early diagnoses and the initiation of treatment.

3. DCP (Des-gamma-Carboxy-Prothrombin, equal to and known as PIVKA-II in Japan)

Protein induced by vitamin K absence-II, a factor of abnormal blood coagulation that arises from deficiency of vitamin K, which was detected in the blood of a high percentage of patients with liver cancer in a study reported in 1984. This factor has since been recognized as a tumor marker of HCC and is currently widely used in routine diagnosis.

4. Tumor marker

A substance whose level becomes elevated in the body when tumors develop; and is utilized as an indicator of tumor formation.


[ Profile of the Involved Companies ]

Sanko Junyaku Co., Ltd.
Representative : Masao Jimbo
Location of headquarters : 1-10-6 Iwamoto-cho, Chiyoda-ku, Tokyo, Japan
Operations: Manufacturing, marketing and import of in vitro diagnostics, laboratory reagents, laboratory instruments, etc.
Capital : 5,262 million yen (50.59% owned by Eisai, as of March 31, 2004)

FUJIREBIO INC.
Representative : Hiromasa Suzuki
Location of headquarters : 2-62-5 Nihonbashi-hamacho, Chuo-ku, Tokyo, Japan
Operations: Manufacturing, marketing, and import/export of in vitro diagnostics, laboratory equipments and other supplies.
Capital : 3,966 million yen (as of December 31, 2003)

Eisai Co., Ltd.
Representative : Haruo Naito
Location of headquarters :4-6-10 Koishikawa, Bunkyo-ku, Tokyo, Japan
Operations: Manufacturing, marketing and export of pharmaceuticals, quasi-drugs, pharmaceutical machinery, etc.
Capital : 44,985 million yen (as of March 31, 2004)